Legend Biotech (LEGN) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viking Therapeutics (VKTX) has outperformed Legend Biotech (LEGN) over the past year, losing 14.3% versus a loss of 41.9%. Over five years, VKTX leads with a +361.4% price change compared with -64.0% for LEGN. Viking Therapeutics is the larger company by market cap ($3.63 billion vs $3.62 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LEGN | VKTX |
|---|---|---|
| Share price | $18.62 | $28.51 |
| Market cap | $3.62B | $3.63B |
| 1-day change | -0.48% | +2.81% |
| YTD return | -13.94% | -21.18% |
| 1-year return | -41.91% | -14.33% |
| 5-year return | -63.96% | +361.40% |
| Forward P/E | 17.73 | — |
| EPS (TTM) | $-0.52 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.03B | $0 |
| Revenue growth (YoY) | +64.04% | — |
| Net income (latest FY) | $-296.80M | $-359.64M |
| Gross margin | 61.41% | — |
| Operating margin | -13.27% | — |
| Net margin | -28.85% | — |
| 52-week high | $37.50 | $43.15 |
| 52-week low | $16.24 | $25.77 |
| Distance from 52-week high | -50.35% | -33.93% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +149.73% | +232.20% |
| Average volume | 2.37M | 4.13M |
| Shares outstanding | 194.49M | 127.17M |
| Employees | 3,200 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VKTX has outperformed LEGN by 27.6 percentage points over the past year.
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
LEGN vs VKTX FAQ
Which is bigger, Legend Biotech or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.63B compared with $3.62B for Legend Biotech (LEGN).
Which stock has performed better over the past year, LEGN or VKTX?
VKTX returned -14.33% over the past 12 months, compared with -41.91% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Legend Biotech and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.